Rebecca Richards is an Oncology physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 49 publications with 2,566 citations (h-index 12); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Highland Ave
Madison, WI 537920001
Telephone
608-263-6420Provider last certified this registry record 2 Sept 2022.
Clinical trials
- Efficacy of Celsi Warmer for the Management of Hypothermic Newborns
Sponsor: William Marsh Rice University
- Mobile High-Resolution Microendoscopy (mHRME) for the Detection of Cervical Dysplasia in El Salvador
Sponsor: William Marsh Rice University
- Pilot Clinical Assessment of Low-cost Infant Incubator in Monitoring Temperature and Treating Hypothermia in Infants
Sponsor: William Marsh Rice University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Chiesi USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- NOT-gated CAR T cells to overcome on-target, off-tumor toxicity in AML
University of Wisconsin-Madison
FY2026$249,048K08CA266930 - NOT-gated CAR T cells to overcome on-target, off-tumor toxicity in AML
University of Wisconsin-Madison
FY2025$249,048K08CA266930 - NOT-gated CAR T cells to overcome on-target, off-tumor toxicity in AML
University of Wisconsin-Madison
FY2024$249,048K08CA266930
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours
Veterinary and Comparative Oncology
2026 - Development of multivalent CAR T cells as dual immunotherapy and conditioning agents
Molecular Therapy Oncology
2025 - Chimeric Antigen Receptors Transmit Co-stimulatory Domain Dependent Piconewton Forces to their Target
bioRxiv (Cold Spring Harbor Laboratory)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
William Busse, MD
University of Wisconsin–Madison
David Andes, MD
University of Wisconsin–Madison
Neil Binkley, MD
University of Wisconsin–Madison
Robert Lemanske, MD
University of Wisconsin–Madison
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”